Good
Mostly Aligned
Patient Risk:
Medium
Summary
Most medication-use, safety, and monitoring-related claims generally align with the provided VERSACLOZ prescribing information. However, several claims overgeneralize or are not fully supported by the label text supplied (notably the emphasis on “Clozapine National Registry,” blanket statements about efficacy comparisons vs other antipsychotics, and interpretation of ANC monitoring frequency).
Category Scores
Accurate Statements
Clozapine is a medication used to treat schizophrenia.
VERSACLOZ indicated for severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment (1.1).
Clozapine is an atypical antipsychotic.
Implied by labeling context (VERSACLOZ is an antipsychotic); no explicit wording provided in the supplied label excerpts, but the excerpts reference antipsychotic use and schizophrenia indication.
Clozapine can be formulated in various strengths, including 100 mg.
Label excerpt provided discusses dosing amounts but does not mention suspension strengths/100 mg. (See unsupported statements for this item.)
Clozapine is used to reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder who have a history of suicidal attempts.
VERSACLOZ indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder judged at chronic risk based on history and recent clinical state (1.2).
The most serious risk of clozapine is agranulocytosis, a potentially life-threatening drop in white blood cell count.
Boxed warning and 5.1 state VERSACLOZ has caused severe neutropenia associated with increased risk of serious and potentially fatal infections; also mentions baseline ANC and not initiating when ANC <1500/µL.
Agranulocytosis risk necessitates regular blood monitoring with clozapine.
Boxed warning: obtain baseline ANC(s) prior to initiation.
Clozapine can cause seizures.
Boxed warning includes Seizure; 5.4 states seizure has occurred and risk is dose-related.
Clozapine can cause myocarditis.
Boxed warning and 5.5: myocarditis has occurred; reactions can be fatal; discontinue and obtain cardiac evaluation upon suspicion.
Clozapine can cause cardiomyopathy.
Boxed warning and 5.5: cardiomyopathy has occurred; reactions can be fatal.
Clozapine can cause orthostatic hypotension.
Boxed warning and 5.2: orthostatic hypotension can occur; reactions include hypotension/bradycardia/syncope and can be fatal.
Sedation is a side effect of clozapine.
No sedation-specific adverse reaction wording appears in the supplied label excerpts.
Weight gain is a side effect of clozapine.
No weight gain-specific adverse reaction wording appears in the supplied label excerpts.
Numerous clinical trials have demonstrated clozapine's efficacy, particularly in treatment-resistant schizophrenia.
The provided excerpts do not include trial text; only the indication statements in 1.1/1.2 are provided.
The frequency of ANC blood tests for clozapine gradually decreases if blood counts remain stable.
The provided boxed warning excerpts mention obtaining baseline ANC(s) but do not provide a schedule showing gradual decrease over time.
Unsupported Statements
Clozapine is typically prescribed to patients who have not responded to other treatments.
Partially aligns with 1.1 (fails to respond adequately to standard antipsychotic treatment), but the claim uses the word “typically prescribed” and “other treatments” without label wording supporting that prescribing practice phrasing.
Clozapine can be formulated in various strengths, including 100 mg.
The supplied label excerpts identify the suspension concentration (50 mg/mL) and discuss dosing titration, but do not state available packaged strengths or specifically “100 mg.”
Clozapine (including the 100 mg dosage) is primarily prescribed for the management of treatment-resistant schizophrenia.
The label excerpt supports indication 1.1 for severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment, but it does not support the phrasing “primarily prescribed” or link to “100 mg” as a particular dose for the indication.
Clozapine is considered when other antipsychotic medications have not been effective in controlling symptoms.
1.1 supports failure to respond adequately to standard antipsychotic treatment; the claim adds “controlling symptoms” wording not present in the supplied label excerpts.
Clozapine works by affecting neurotransmitters in the brain, particularly dopamine and serotonin.
No mechanism-of-action explanation is provided in the supplied label excerpts.
Clozapine modulates the activity of dopamine and serotonin in specific pathways.
No such mechanism/pathways are provided in the supplied label excerpts.
Clozapine helps to alleviate psychotic symptoms like hallucinations and delusions.
The supplied label excerpts state schizophrenia indication and reduction of risk of recurrent suicidal behavior but do not list symptom-level effects such as hallucinations/delusions.
Agranulocytosis risk necessitates regular blood monitoring with clozapine.
The label excerpts provided explicitly require baseline ANC(s), but do not describe the ongoing monitoring frequency as “regular” beyond baseline.
Clozapine is typically prescribed under strict monitoring programs like the Clozapine National Registry.
The supplied label excerpts do not mention the Clozapine National Registry.
Numerous clinical trials have demonstrated clozapine's efficacy, particularly in treatment-resistant schizophrenia.
The supplied label excerpts do not include trial summaries supporting this statement.
Studies have shown clozapine significantly reduces positive and negative symptoms of schizophrenia compared to other antipsychotics.
The supplied label excerpts do not provide efficacy comparisons or positive/negative symptom outcomes.
Clozapine is effective in reducing suicidal ideation in at-risk patients.
Label 1.2 states reducing risk of recurrent suicidal behavior in patients at chronic risk based on history and recent clinical state; it does not specifically state “suicidal ideation” or “at-risk patients” wording.
Due to the risk of agranulocytosis, patients on clozapine require frequent blood tests to monitor their absolute neutrophil count (ANC).
Boxed warning excerpts include baseline ANC(s) and initiation criteria, but do not provide a statement that patients require frequent ANC tests or a frequency.
The frequency of ANC blood tests for clozapine is highest when starting the medication.
The supplied label excerpts provided do not include an ANC monitoring schedule showing frequency is highest at initiation.
The frequency of ANC blood tests for clozapine gradually decreases if blood counts remain stable.
The supplied label excerpts do not provide a monitoring schedule indicating gradual decrease with stable counts.
Sedation is a side effect of clozapine.
Sedation is not mentioned in the supplied adverse reaction excerpts.
Weight gain is a side effect of clozapine.
Weight gain is not mentioned in the supplied adverse reaction excerpts.
Contradictions
Low
AI Statement
Clozapine is effective in reducing suicidal ideation in at-risk patients.
Label Reference
VERSACLOZ indication is to reduce the risk of recurrent suicidal behavior in patients at chronic risk based on history and recent clinical state (1.2).
Important Omissions
The label’s boxed warning includes ‘Increased mortality in elderly patients with dementia-related psychosis’ and states VERSACLOZ is not approved for that use; none of the provided claims mention this population restriction.
Importance:
Moderate
The label states VERSACLOZ initiation is not recommended with baseline ANC <1500/µL (boxed warning), but the monitoring-related claims do not include this initiation criterion.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims about safety (seizures, myocarditis, cardiomyopathy, orthostatic hypotension, severe neutropenia) are directionally consistent with the boxed warning/precautions excerpts, but other statements about ongoing ANC monitoring frequency and registry-like monitoring are not supported by the provided label text. Missing the elderly dementia-related psychosis boxed warning and ANC initiation threshold reduces label completeness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Overgeneralizations/unsupported specifics not present in the supplied label excerpts (e.g., Clozapine National Registry, detailed ANC monitoring frequency, symptom-level efficacy comparisons, dopamine/serotonin mechanism, sedation/weight gain).
Suggested Improvement
Restrict claims to what is explicitly supported by the provided VERSACLOZ label excerpts: use label wording for indications (fail to respond adequately; reduce risk of recurrent suicidal behavior), mention boxed-warning safety elements without adding unsupported registry or monitoring-frequency details, and include the elderly dementia-related psychosis boxed warning/approval restriction when describing risks.